pMell7 is recognised by anti-melanoma CTL and MAbs
1996

Recognition of pMell7 by Antibodies and T Cells in Melanoma

publication Evidence: moderate

Author Information

Author(s): GJ Adema, ABH Bakker, AJ de Boer, P Hohenstein, CG Figdor

Primary Institution: University Hospital Nijmegen St. Radboud

Hypothesis

pMell7 is a target for immunotherapy in malignant melanoma due to its recognition by specific antibodies and T cells.

Conclusion

The study demonstrates that pMell7 is recognized by multiple antibodies used for melanoma diagnosis and is effectively targeted by anti-melanoma T cells.

Supporting Evidence

  • pMell7 is recognized by three different monoclonal antibodies used to diagnose malignant melanoma.
  • Cells transfected with pMell7 cDNA are specifically lysed by TIL1200, a melanoma patient-derived T-cell line.
  • Both gplOO and pMell7 are expressed simultaneously in melanoma cells, contributing to immunogenicity.

Takeaway

Researchers found that a protein called pMell7 can be spotted by special antibodies and attacked by immune cells in melanoma, which could help in treating the disease.

Methodology

The study involved cloning the cDNA of pMell7, transfecting it into melanoma cell lines, and testing for recognition by antibodies and T cells.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication